Prolonged antidiabetic effect of zinc-crystallized insulin loaded glycol chitosan nanoparticles in type 1 diabetic rats

被引:10
作者
Jo, Hyung Gon [1 ]
Min, Kyung Hyun [1 ]
Nam, Tae Hwan [1 ]
Na, Seong Ju [1 ]
Park, Jae Hyung [1 ]
Jeong, Seo Young [1 ]
机构
[1] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul 130701, South Korea
关键词
basal insulin; blood glucose control; nanoparticles; type; 1; diabetes;
D O I
10.1007/s12272-001-1247-9
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
New basal insulin formulation was designed and their structural characteristics were investigated in vitro and biological activities in type 1 diabetic rats. Zinc-crystallized insulin was physically loaded into hydrophobically modified glycol chitosan (HGC) nanoparticles by a dialysis method. The series of insulin-HGC formulations were prepared with different feed weight ratio of insulin to HGC from 0.5:1 to 4:1. The loading contents of insulin and size distribution of insulin-HGCs were characterized, and blood glucose responses were investigated in streptozotocin-induced diabetic rats after single subcutaneous injection of regular insulin and insulin-HGCs. The highest loading efficiency and content were obtained in insulin-HGC when a 1:1 feed weight ratio of insulin to HGC was employed. The hydrodynamic diameter of insulin-HGC nanoparticles were in the range of 200 to 500 nm with narrow size distribution. Insulin-HGC effectively sustained insulin release up to 40% within 12 hours followed by a slower controlled release. Insulin-HGC showed an extended blood glucose lowering effect up to 24 h and provided normal blood glucose levels after oral glucose (1.5 g/kg) load at 24 hours post-injection while regular insulin showed severe hypoglycemia. The prolonged time action profiles and low variability of insulin-HGC formulation resulted in improved blood glucose control in diabetic rats and fulfilled a pattern desirable of a basal insulin.
引用
收藏
页码:918 / 923
页数:6
相关论文
共 16 条
[1]
Agu RU, 2001, RESP RES, V2, P198
[2]
INSULIN PHARMACOKINETICS [J].
BINDER, C ;
LAURITZEN, T ;
FABER, O ;
PRAMMING, S .
DIABETES CARE, 1984, 7 (02) :188-199
[3]
Insulin analogs with improved pharmacokinetic profiles [J].
Brange, J ;
Volund, A .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 35 (2-3) :307-335
[4]
Concept, strategies, and feasibility of noninvasive insulin delivery [J].
Cefalu, WT .
DIABETES CARE, 2004, 27 (01) :239-246
[5]
Protein drug stability: A formulation challenge [J].
Frokjaer, S ;
Otzen, DE .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (04) :298-306
[6]
New concept for long-acting insulin - Spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin [J].
Gershonov, E ;
Shechter, Y ;
Fridkin, M .
DIABETES, 1999, 48 (07) :1437-1442
[7]
Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin [J].
Hamilton-Wessler, M ;
Ader, M ;
Dea, M ;
Moore, D ;
Jorgensen, PN ;
Markussen, J ;
Bergman, RN .
DIABETOLOGIA, 1999, 42 (10) :1254-1263
[8]
Biodegradable nanoparticles for drug delivery and targeting [J].
Hans, ML ;
Lowman, AM .
CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE, 2002, 6 (04) :319-327
[9]
Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel (Reprinted from Journal of Controlled Release, vol 109, pg 1, 2005) [J].
Kim, JH ;
Kim, YS ;
Kim, S ;
Park, JH ;
Kim, K ;
Choi, K ;
Chung, H ;
Jeong, SY ;
Park, RW ;
Kim, IS ;
Kwon, IC .
JOURNAL OF CONTROLLED RELEASE, 2006, 111 (1-2) :228-234
[10]
Physicochemical characteristics of self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid [J].
Kwon, S ;
Park, JH ;
Chung, H ;
Kwon, IC ;
Jeong, SY ;
Kim, IS .
LANGMUIR, 2003, 19 (24) :10188-10193